Selexipag for the treatment of pulmonary arterial hypertension.
Sharma K.
Expert Rev Respir Med · editorial · DOI 10.1586/17476348.2016.1121103 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för selexipag. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
9 hitsSelexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, GRIPHON Investigators.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1503184Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.5b00698Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
Baldoni D, Bruderer S, Muhsen N, Dingemanse J.
Int J Clin Pharmacol Ther · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.5414/cp202318Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Äänismaa P, Halabi A, Dingemanse J.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/bcp.12650Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, Mukai H.
Am J Cardiovasc Drugs · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40256-015-0117-4A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Hoch M, Darpo B, Remenova T, Stoltz R, Zhou M, Kaufmann P, Bruderer S, Dingemanse J.
Drug Des Devel Ther · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2147/dddt.s75565Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Bruderer S, Hurst N, Kaufmann P, Dingemanse J.
Pharmacology · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1159/000367630Selexipag for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N, Lang IM.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2014.876007